Summary & Overview
HCPCS J1448: Trilaciclib Injection, 1 mg
HCPCS Level II code J1448 denotes a 1 mg unit of trilaciclib administered by injection. Trilaciclib is a pharmacologic agent used in oncology care protocols; accurate coding for this drug is important for claims processing, therapy tracking, and national drug utilization monitoring. This code matters nationally as biologic and oncology drug spending continues to be a major driver of specialty pharmacy and infusion costs.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coverage patterns and payer considerations, benchmarked utilization and cost context where available, and relevant clinical context tied to infusion-based oncology services. The publication summarizes common billing practices for unit-based HCPCS drug reporting, typical sites of service for injectable oncology therapies, and highlights areas where policy updates or payer guidance can affect claim adjudication.
The piece provides actionable reference material for billing teams, revenue cycle managers, and policy analysts seeking a concise national view of J1448 usage and billing implications. Data not available in the input will be clearly identified in the sections that follow.
Billing Code Overview
HCPCS Level II code J1448 represents the drug product trilaciclib, billed per 1 mg unit. This code is used for administration of trilaciclib as an injectable therapy.
-
Service type: Injection
-
Typical site of service: Hospital outpatient infusion center, oncology clinic, or other ambulatory infusion settings
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult receiving myelotoxic chemotherapy for extensive-stage small cell lung cancer or another malignancy where prophylactic myeloprotection is indicated. The oncology clinic schedules J1448 (injection, trilaciclib, 1 mg) to be administered intravenously prior to cytotoxic chemotherapy on the day of treatment. The workflow includes verification of the chemotherapy order, review of current blood counts and infusion history, confirmation of indications and consent, preparation of the appropriate trilaciclib dose by pharmacy, and administration by an infusion nurse or oncology-trained clinician in an outpatient infusion center or hospital oncology unit. Vital signs and pre-infusion assessment are completed, the drug is infused per protocol before the cytotoxic agent, and the patient is monitored for immediate adverse reactions. Documentation includes the drug name and J1448 HCPCS code, NDC or lot number if required by payer, dose administered (in mg), route (intravenous), start and stop times, applicable modifier(s), and associated ICD-10 diagnosis that supports medical necessity for myeloprotection during chemotherapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Default reporting when no specific modifier applies |